According to researcher Anne Robertson, the bladder is not considered a particularly glamorous organ, despite hosting many of ...
TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...
The IMvigor010 trial showed that Signatera-guided treatment with Tecentriq improved disease-free survival and overall ...
Bladder cancer is the ninth most common cancer in the world, the fourth most common cancer in men, and the 11th most common ...
A new U.S. survey conducted by The Harris Poll on behalf of ImmunityBio, Inc. (NASDAQ: IBRX) reveals that many people living with non-muscle invasive bladder cancer (NMIBC) feel left out of critical ...
A slow drug-release system has proven highly effective in treating certain bladder cancer patients whose tumors were previously unresponsive to therapy. A new targeted drug delivery system known as TA ...
The experts agreed that perioperative approaches in muscle-invasive bladder cancer continue to evolve. Ongoing data will ...
The bladder cancer treatment landscape is rapidly evolving, particularly for patients who don’t respond to bacillus ...
Growth hormone receptor (GHR) signaling in bladder cancer is associated with advanced tumor stages and poor survival outcomes. High GHR expression in tumors up-regulates genes involved in drug ...
Once a UTI develops, “the most common and effective treatment is a course of antibiotics,” says Adair. The specific ...
Welltica+ on MSN
Tiny implant eliminates bladder cancer in 82% of patients
A new slow-release implant has shown unprecedented success in wiping out bladder cancer in more than 80 percent of patients, ...
The TAR‑200 slow‑release bladder implant cleared tumours in 82% of patients with high‑risk non‑muscle‑invasive bladder cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback